Recommendations on treatment strategies in hypertensivepatientswithmetabolic disorders


In 2013 experts of The Russian Medical Society on Arterial Hypertension (RMSAH) had prepared recommendations about management of patients with arterial hypertension (AH) and metabolic disorders (such as obesity, carbohydrate and lipid metabolism, hyperuricemia) and which chapters about diagnosis and correction were expanded, compared to the previous RMSAH recommendations. We also added a chapter about management of patients with AH and type 2 diabetes (T2D). Treatment and diagnosis algorithms of metabolic syndrome (MS) and T2D, discussed in these recommendations, will help us early identify and correct these disorders and will reduce cardiovascular events in patients with AH, even mortality one.

Full Text

Restricted Access

About the authors

Yu V Zhernakova


I E Chazova



  1. Motillo S, Filion K.B, Genest J et al. The metabolic syndrome and cardiovascular risk a systematic review and meta - analysis. J Am Coll Cardiol 2010; 56 (14): 1113-32.
  2. Kotseva K. EUROASPIRE IV reveals success and challenges in secondary prevention of CVD across Europe.
  3. Jordan J, Yumuk V, Schalaich M et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension.J Hypertens 2012; 30 (6): 1047-55.
  4. Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Дис. … д - ра мед. наук. М., 2012.
  5. Шарипова Г.М. Особенности поражения органов - мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Дис. … д - ра мед. наук. М., 2009.
  6. Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-7
  7. Nakano S, Fukuda M, Hotta F et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998; 47 (9): 1501-6.
  8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.
  9. Zeljko Reiner, Alberico L.Catapano, Guy De Backer et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32, 1769-818.
  10. Jose Luis Zamorano, Stephan Achenbach, Helmut Baumgartner et al. The Task Force on diabetes, pre - diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal doi: 10.1093/eurheartj/eht108.
  11. Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Int J Hypertens 2013; 2013: 1-9. doi: 10.1155/2013/541689.
  12. Sharma A.M, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004; 18: 669-75.
  13. Prichard B.N.C, Simmons R, Rooks J et al. A double - blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl. 4): S45-S49.
  14. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 (Suppl. 4): S42-S44.
  15. Trieb G, Jager B, Hughes P.R, Gardosch von Krosigk P-P. Long - term evaluation of the antihypertensive efficacy and tolerability of the orally - acting imidazoline I1 receptor agonist moxonidine. Eur J Clin Res 1995; 7: 227-40.



Abstract - 7

PDF (Russian) - 7



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies